




The relative strengths and weaknesses of NRX Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NRX Pharmaceuticals Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 9.1% points. The greatest weakness of NRX Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 121% points.

The company's Economic Capital Ratio, given in the ranking table, is 20%, being 195% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	3,302
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,863
Liabilities, Non-Current	0
Other Assets	349
Other Compr. Net Income	0
Other Expenses	-1,202
Other Liabilities	5,011
Other Net Income	-6,624
Other Revenues	0
Property and Equipment	0
Research and Development	6,199
Selling, General and Administrative Expense	13,505

Output Variable	Value in 1000 USD
Assets	3,651
Liabilities	26,874
Expenses	18,502
Revenues	0
Stockholders Equity	-23,223
Net Income	-25,126
Comprehensive Net Income	-25,126
BaseVar	27,826
ECR before LimitedLiability	-496%
Economic Capital Ratio	20%